VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RFL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RFLRafael Holdings, Inc.
$2.34$86M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

RFL logoRafael Holdings, Inc.(RFL)Earnings, Financials & Key Ratios

RFL•NYSE
$2.76
Price updated Jul 6, 2026
SectorReal EstateIndustryReal Estate ServicesSub-IndustryReal estate owners and developers
AboutRafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.Show more
  • Revenue$917K+44.0%
  • EBITDA-$26M+74.8%
  • Net Income-$31M+11.3%
  • EPS (Diluted)-1.04+28.3%
  • Gross Margin53.98%-28.8%
  • EBITDA Margin-2815.81%+82.5%
  • Operating Margin-2847.22%+82.3%
  • Net Margin-3328.24%+38.4%
  • ROE-33.06%+12.1%

RFL Price & Volume

Rafael Holdings, Inc. (RFL) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Losses Challenge Asset Liquidation Value

Investment Thesis • Updated 2026Q3

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical Trial Burn Rate

Key Thesis Takeaways

  • Rafael Holdings faces a structural disconnect between its modest real estate-derived revenue and the high administrative costs required to sustain its oncology-focused pharmaceutical pipeline.
  • While the company maintains a cash position of $30.5 million as of 2026Q3, the consistent erosion of its asset base and deep operating losses suggest a precarious long-term outlook.
  • Investors should monitor the company's ability to preserve its remaining liquidity against the backdrop of a $252.7 million accumulated deficit.

Verdict Logic

the company's persistent cash burn and negative operating margins, highlighted by a -38.4% operating margin in 2026Q3, suggest that the current business model remains fundamentally unsustainable.

RFL Growth Metrics

Rafael Holdings, Inc. (RFL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-28.51%
3 Years30.78%
TTM33.88%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-42.19%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM27.39%

Return on Capital

10 Years-23.37%
5 Years-44.12%
3 Years-51.03%
Last Year-27.22%

RFL Recent Earnings

Rafael Holdings, Inc. (RFL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
Q3 2026Latest
Jun 11, 2026
Metric
Actual
Est
EPS
$0.15
—
Rev
$179,000
—
Q2 2026
Mar 16, 2026
Metric
Actual
Est
EPS
$0.13
—
Rev
$211,000
—
Q4 2025
Dec 11, 2025
Metric
Actual
Est
EPS
$0.19
—
Rev
$240,000
—
Q4 2025
Oct 29, 2025
Metric
Actual
Est
EPS
$0.28
—
Rev
$350,000
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026LatestJun 11, 2026
$0.15
$179,000
Q2 2026Mar 16, 2026
$0.13
$211,000
Q4 2025Dec 11, 2025
$0.19
$240,000
Q4 2025Oct 29, 2025
$0.28
$350,000
Based on last 12 quarters of dataView full earnings history →

Latest RFL News

Recent stock market news and headlines for Rafael Holdings, Inc. (RFL)

Newsfile Corp·1 day ago
AuMEGA Metals Appoints Rafael Gradim as President

Highly accomplished executive with extensive exploration, strategy, corporate development and capital markets experience to lead exploration Edmonton, Alberta--(Newsfile Corp. - July 6, 2026) - AuMEGA Metals Ltd. (ASX: AAM) (TSXV: AUM) (OTCQB: AUMMF) ("AuMEGA" or "the Company") announces that Michael Skead will step down as President of the Company, effective immediately, for personal reasons.

Seeking Alpha·Jun 29, 2026
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out.

Reuters·Jun 23, 2026
Heineken names Rafael Oliveira as CEO

Dutch beer maker Heineken has appointed Rafael Oliveira as its new chair and CEO, it ​said on Tuesday, becoming one of several alcoholic drinks makers ‌to seek to galvanise sales through a change of leadership.

GlobeNewsWire·Jun 23, 2026
Heineken N.V. announces nomination of Rafael Oliveira as Chief Executive Officer

Amsterdam, 23 June 2026 Heineken N.V. announces nomination of Rafael Oliveira as Chief Executive Officer The Supervisory Board of Heineken N.V.

Peers Comparison

Key metrics vs top competitors for Rafael Holdings, Inc. (RFL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RFL logoRFLRafael Holdings, Inc.Current
$2.76$101.43M-2.6543.96%-3328.24%-33.06%—
IMVT logoIMVTImmunovant, Inc.
$38.60$7.92B-13.94——-68.16%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$4.79$194.47M3.9336.55%-19.55%-3.39%—
CASI logoCASICASI Pharmaceuticals, Inc.
$0.15$2.33M-0.06-15.77%-183.93%——
CRIS logoCRISCuris, Inc.
$5.94$11.58M-0.51-13.43%-299.66%——
HALO logoHALOHalozyme Therapeutics, Inc.
$80.78$9.58B31.5537.55%23.13%126.27%—

Compare RFL vs Peers

Rafael Holdings, Inc. (RFL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for RFL.

Scale Benchmark

vs IQV

Larger-name benchmark to compare RFL against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, TPVG, CASI, CRIS

RFL SEC Filings & Documents

Rafael Holdings, Inc. (RFL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jun 11, 2026·SEC

Material company update

Jun 10, 2026·SEC

Material company update

Apr 22, 2026·SEC

10-K Annual Reports

3
FY 2025

Oct 29, 2025·SEC

FY 2024

Nov 7, 2024·SEC

FY 2023

Oct 30, 2023·SEC

10-Q Quarterly Reports

6
FY 2026

Jun 11, 2026·SEC

FY 2026

Mar 16, 2026·SEC

FY 2025

Dec 12, 2025·SEC

Get notified when RFL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RFL Frequently Asked Questions

Rafael Holdings, Inc. (RFL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Rafael Holdings, Inc.'s revenue?

Rafael Holdings, Inc. (RFL) reported $1.0M in revenue for fiscal year 2025. This represents a 82% decrease from $5.6M in 2016.

How fast is Rafael Holdings, Inc. growing?

Rafael Holdings, Inc. (RFL) grew revenue by 44.0% over the past year. This is strong growth.

Is RFL profitable?

Rafael Holdings, Inc. (RFL) reported a net loss of $32.6M for fiscal year 2025.

Dividend & Returns
What is RFL's return on equity?

Rafael Holdings, Inc. (RFL) has a return on equity (ROE) of -33.1%. Negative ROE indicates the company is unprofitable.

What is Rafael Holdings, Inc.'s free cash flow?

Rafael Holdings, Inc. (RFL) had negative free cash flow of $32.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in RFL back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →